Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation McGahan L. Atezolizumab (Tecentriq™) for the treatment of locally advanced and metastatic urothelial carcinoma. Vienna: Ludwig Boltzmann Institut fuer Health Technology Assessment (LBIHTA). DSD: Horizon Scanning in Oncology No. 61. 2016 Authors' conclusions Although it is the first PD-L1 inhibitor to receive approval based on the tumour response rate and durability reported in cohort 2 of the phase II trial IMvigor 210, patients were not followed long enough to adequately determine the median duration of response (DOR), whether atezolizumab reduces mortality or prolongs survival for some or all responders, how treatment may affect disease progression or recurrence, or to identify all potential adverse events. Further studies are needed to examine patient reported outcomes (PROMs), patient reported experiences (PREMs), and quality of life measures to determine whether atezolizumab provides adequate clinical benefit in terms of improving the symptoms and severity of locally advanced and MUC. Indexing Status Subject indexing assigned by CRD MeSH Carcinoma, Transitional Cell; Humans; Urologic Neoplasms Language Published English Country of organisation Austria English summary An English language summary is available. Address for correspondence Ludwig Boltzmann Institute fuer Health Technology Assessment (LBI-HTA), Garnisongasse 7 rechte Stiege Mezzanin (Top 20), 1090 Vienna, Austria. Tel: +43 1 236 8119 - 0 Fax: +43 1 236 8119 - 99 AccessionNumber 32016001022 Date abstract record published 11/10/2016 |